Generating a highly expressing, regulatory compliant clonal cell line is key when developing a biopharmaceutical. Yet cell line development is labor-intensive, time consuming and costly.

The production of a high-quality and productive cell line requires both an expression system which yields high expressing clones and a workflow which allows selection of the highest producing clones.

In this webinar, you’ll discover how combining a single-cell analysis platform with a novel glutamine synthetase-Chinese hamster ovary (GS-CHO) expression system can yield highly productive, scalable, clonal cell lines for developing biopharmaceuticals.

To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules–the lipids and the genetic cargo–is paramount.

Cell therapies often involve introduction of genetically transformed cells into a patient. Recently there has been renewed interest in non-viral gene modification for this application as an alternative to lentiviral vectors.

This exclusive Q&A event invites you to ask anything about the world of predatory conferences to our expert speaker.

In this webinar, Scalable production of AAV from shake flasks to 1,000 L single use bioreactors using the Gibco™ CTS™ AAV‑MAX Production System, Jon Zmuda from Thermo Fisher Scientific will share several case studies

This talk delves into the fascinating world of aptamers. Aptamers are short single-stranded nucleic acid oligomers, either DNA or RNA, known for their ability to form intricate three-dimensional structures. The development of aptamers relies on SELEX (systematic evolution of ligands by exponential enrichment), a process that allows researchers to fine-tune their characteristics during selection.